

MALAYSIAN ORGANISATION OF PHARMACEUTICAL INDUSTRIES (MOPI)

28 JUNE 2023

FOR IMMEDIATE RELEASE

MR. CH'NG KIEN PENG AS THE NEW PRESIDENT OF MOPI

The Malaysian Organisation of Pharmaceutical Industries (MOPI) is pleased to announce Mr. Ch'ng Kien Peng as the new President effective 27 June 2023 for a two-year term.

Mr. Ch'ng brings a wealth of experience to MOPI, with 33 years in the pharmaceutical industry. He rose through the ranks at GlaxoSmithKline in Technical Services, Manufacturing, and QA roles before assuming the position of General Manager of Manufacturing at Xepa-Soul Pattinson (Malaysia) Sdn. Bhd. His dedication to excellence led to his promotion to Executive Director of Xepa in 2015, a position he continues to hold. Furthermore, Mr. Ch'ng serves as Senior Vice President and subsequently retitled to Chief Operating Officer, Manufacturing Group for Apex Healthcare Berhad (AHB), Xepa's holding company, overseeing in-group product development and pharmaceutical manufacturing businesses. A registered pharmacist, Mr. Ch'ng graduated with a Bachelor of Pharmacy (Honours) from the Universiti Sains Malaysia (USM) and an MBA from Heriot-Watt University, Edinburgh. His prior engagement with MOPI includes serving as Vice President from 2011 to 2014 and from 2021 to 2023.

We would like to announce the MOPI's Executive Committee (ExCo) line-up for the term 2023-2025:

- 1. Mr. Ch'ng Kien Peng President (Xepa-Soul Pattinson (Malaysia) Sdn. Bhd.)
- 2. Mr. Diong Sing Peng Vice President (Pahang Pharmacy Sdn. Bhd.)
- 3. Dato' Farshila Binti Emran Vice President (GoodScience Sdn. Bhd.)
- 4. Mr. David Ho Sue San (Hovid Berhad)
- 5. Ms. Grace Yap Yen Mee (Y.S.P Industries (M) Sdn. Bhd.)
- 6. Mr. Jimmy Piong Teck Onn (Kotra Pharma (M) Sdn. Bhd.)
- 7. Mr. Peter Rayar Sowrimuthu (KCK Pharmaceutical Industries Sdn. Bhd.)
- 8. Mr. Redziwan Saari (Ain Medicare Sdn. Bhd.)
- 9. Ms. Sabrina Haron (Duopharma Manufacturing (Bangi) Sdn. Bhd.)
- 10. Mr. Mohd Saharuddin Othman (Idaman Pharma Manufacturing Sdn. Bhd.)
- 11. Mr. Wan Amir-Jeffery Bin Wan Abdul Majid (Duopharma (M) Sdn. Bhd.)
- 12. Mr. Yusni Rizal bin Dato' Khairul (Pharmaniaga Manufacturing Berhad)

We also would like to take this opportunity to extend our deepest gratitude to our outgoing President, Mr. Billy Urudra, for his transformative contributions since 2018. Mr. Urudra has been instrumental in rebranding MOPI and solidifying its position as a key stakeholder in the Malaysian pharmaceutical industry. His vision, advocacy, and commitment to capacity building have greatly impacted MOPI, and he has left a legacy of excellence and dedication.

As such, in recognition of his remarkable achievements, the MOPI ExCo members have collectively appointed Mr. Billy Urudra to lead the MOPI Secretariat as the Executive Director. In this vital role, he will be harnessing his expertise and leadership qualities to supercharge both our ongoing and future efforts and initiatives.

As a trade association, MOPI plays an integral role in fostering collaboration among stakeholders to create a conducive ecosystem for the growth and development of the local pharmaceutical manufacturing industry. The organization is committed to enhancing healthcare quality and medicine security through the provision of quality and affordable medicines for all.

We are excited to usher in this new chapter under Mr. Ch'ng's leadership and the new ExCo line-up and look forward to continued collaboration and engagement with all stakeholders.

*End of Press Statement *

ABOUT MOPI

The Malaysian Organisation of Pharmaceutical Industries (MOPI), established in 1981, is an association representing local pharmaceutical manufacturers and its supporting industries in Malaysia. With a strong membership of 52 companies, MOPI members currently supply about 50% of the country's demand for prescription medicines and are the largest suppliers of prescription medicines to the Ministry of Health (MOH). MOPI is dedicated to advancing the pharmaceutical sector in Malaysia and promotes the supply of quality and affordable medicines to all.

For more information, please do not hesitate to contact Mr. Sharvin A. Subramaniam (sharvin.mopi@gmail.com).